Crohn's disease nursing: pathophysiology, assessment, and NCLEX review

Crohn’s disease is a chronic, relapsing-remitting inflammatory bowel disease that can affect any segment of the gastrointestinal tract from the mouth to the anus, with a predilection for the terminal ileum and proximal colon. Unlike ulcerative colitis, which is confined to the colonic mucosa, Crohn’s involves transmural inflammation across all layers of the bowel wall and is not curable with surgery. For nursing students, understanding the pathophysiology, distinguishing clinical features, and anticipating complications is foundational for both clinical practice and NCLEX success.

This reference covers everything you need for Crohn’s disease nursing care – from cellular mechanisms and diagnostic workup to nursing interventions, medication management, and NCLEX decision scenarios. Use it alongside the IBD nursing overview, the nursing lab values cheat sheet, and the drug classifications guide for a complete GI knowledge base.

Crohn’s disease at a glance

Crohn’s disease vs ulcerative colitis

Distinguishing Crohn’s disease from ulcerative colitis is among the most tested concepts in NCLEX GI questions. The differences arise from where each disease involves the bowel and how deeply it penetrates.

Memory cue: Crohn’s disease: Can occur anywhere, Cobblestone, Creeping fat, Complications (fistulas). Ulcerative colitis: Uniform and continuous, Upper layers only (mucosa), Ulcerative and bloody.

Pathophysiology

Crohn’s disease results from a dysregulated mucosal immune response in genetically susceptible individuals. The strongest genetic risk factor is a mutation in the NOD2 gene (chromosome 16), which encodes a pattern-recognition receptor involved in bacterial surveillance. When this innate immune sensing is impaired, the gut microbiome triggers an exaggerated adaptive immune response.

Environmental triggers – enteric pathogens, NSAIDs, cigarette smoke, and alterations in the gut microbiome – activate CD4+ T-helper cells within the intestinal lamina propria. In Crohn’s disease, the immune response is predominantly Th1-mediated, characterized by excess production of TNF-alpha, IFN-gamma, and the interleukins IL-12 and IL-23. These cytokines drive sustained inflammation that penetrates through all layers of the bowel wall – a key distinction from ulcerative colitis.

The transmural nature of Crohn’s inflammation produces several characteristic findings:

• Cobblestone mucosa: Deep ulcerations separated by areas of edematous, regenerating mucosa create a cobblestone appearance on endoscopy.
• Skip lesions: Inflamed segments alternate with grossly normal bowel – a pattern that can involve any level of the GI tract simultaneously.
• Non-caseating granulomas: Collections of epithelioid macrophages form in the bowel wall and mesenteric lymph nodes in roughly a third of cases. Their presence strongly supports Crohn’s disease and is one of the most discriminating histologic findings, but it is not strictly pathognomonic – non-caseating granulomas also appear in sarcoidosis, common variable immunodeficiency, and some mycobacterial infections, so intestinal tuberculosis in particular must be excluded before treating.
• Creeping fat: Mesenteric adipose tissue wraps around the serosal surface of inflamed bowel loops, visible at surgery.
• String sign: Severe luminal narrowing from edema or fibrosis produces a thin, string-like appearance of the terminal ileum on barium contrast studies or CT enterography.

Over time, recurrent inflammation leads to fibrosis and stricture formation. Transmural ulceration can create fistulous tracts between adjacent loops of bowel, the bladder, vagina, or skin.

Clinical presentation

Gastrointestinal symptoms

The classic presentation of Crohn’s disease includes:

• Right lower quadrant (RLQ) pain: The terminal ileum is the most commonly affected segment. RLQ cramping pain – often worsening after meals – results from inflammation, obstructive symptoms, or mesenteric involvement.
• Diarrhea: Typically non-bloody or only mildly blood-streaked. This differs from ulcerative colitis, where hematochezia is a defining feature. Diarrhea results from impaired absorption, bile salt malabsorption, and increased intestinal secretions.
• Weight loss and malnutrition: Impaired nutrient absorption across inflamed segments, food avoidance due to pain, and increased metabolic demand from chronic inflammation all contribute.
• Fatigue: A combination of anemia, malnutrition, chronic pain, and inflammatory cytokines produces significant fatigue during active disease.

Perianal disease

Perianal involvement occurs in up to 35% of patients with Crohn’s disease and can precede bowel symptoms. Findings include:

• Perianal fistulas (connection between anal canal and perianal skin)
• Perianal abscesses
• Skin tags
• Anal fissures

Perianal disease is a hallmark of Crohn’s – it does not occur in ulcerative colitis.

Extraintestinal manifestations

Systemic inflammation extends beyond the bowel in many patients. Common extraintestinal manifestations include:

• Joints: Peripheral arthritis (correlates with bowel activity) and sacroiliitis or ankylosing spondylitis (independent of bowel activity)
• Skin: Erythema nodosum (tender, raised red nodules, usually on shins – correlates with bowel flares), pyoderma gangrenosum
• Eyes: Uveitis, episcleritis
• Liver/biliary: Primary sclerosing cholangitis (more common in UC but occurs in Crohn’s), cholelithiasis from ileal bile salt malabsorption
• Renal: Calcium oxalate nephrolithiasis (increased oxalate absorption from the colon when fat malabsorption is present)

Vitamin B12 deficiency

Terminal ileum disease is a key Crohn’s complication: the terminal ileum is the exclusive site of vitamin B12 (cobalamin) absorption. When the terminal ileum is inflamed or has been surgically resected, B12 absorption is severely impaired, leading to megaloblastic anemia, peripheral neuropathy, and subacute combined degeneration of the spinal cord over time. Monthly intramuscular B12 injections are required for patients with terminal ileum resection.

Diagnosis

No single test confirms Crohn’s disease. Diagnosis requires correlation of clinical findings with endoscopic, histologic, and imaging evidence.

Colonoscopy with biopsy is the gold standard. Endoscopy reveals skip lesions, cobblestone mucosa, aphthous ulcers, and rectal sparing. Non-caseating granulomas are found on biopsy in roughly a third of patients; when present they strongly support the diagnosis, but their absence does not exclude Crohn’s disease.

CT or MRI enterography evaluates the small bowel – segments inaccessible to colonoscopy. Findings include bowel wall thickening, mucosal enhancement, mesenteric stranding, and the string sign at the terminal ileum. MRI is preferred in younger patients to avoid cumulative radiation exposure.

Laboratory markers:

• CRP and ESR: Elevated during active inflammation; useful for monitoring disease activity and treatment response
• Fecal calprotectin: Elevated in active intestinal inflammation; useful for distinguishing IBD from irritable bowel syndrome and monitoring mucosal healing
• CBC: Anemia (normocytic from chronic disease, or macrocytic from B12/folate deficiency, or microcytic from iron deficiency with GI blood loss)
• Albumin and prealbumin: Markers of nutritional status and disease severity; low albumin correlates with increased complications
• B12 level: Check in all patients with terminal ileum involvement

See the nursing lab values cheat sheet for normal ranges and interpretation guidance.

Nursing assessment

A thorough, structured assessment guides care priorities during both acute flares and outpatient monitoring.

Bowel pattern and symptoms

Document stool frequency, consistency, and the presence or absence of blood. Characterize pain: location (RLQ is classic), quality, relationship to meals, and what provides relief. Assess for urgency and tenesmus. Quantify diarrhea episodes per 24-hour period during flares.

Nutritional status

Weigh patients at every visit. Compare current weight to baseline and note trends over weeks to months. Assess dietary intake using a 24-hour recall. Screen for deficiencies: B12, folate, iron, zinc, magnesium, fat-soluble vitamins (A, D, E, K) in patients with significant ileal disease or fat malabsorption.

Fluid and electrolyte status

Frequent diarrhea depletes sodium, potassium, magnesium, and bicarbonate. Assess for signs of dehydration (dry mucous membranes, decreased skin turgor, concentrated urine, tachycardia) and electrolyte disturbances. Review serum electrolytes, BUN, and creatinine. See the electrolyte imbalances nursing guide for detailed assessment and intervention.

Skin integrity

Assess perianal skin at every encounter for fistula openings, abscess formation, induration, erythema, and skin breakdown. Patients with enterocutaneous fistulas require wound assessment including drainage characteristics, odor, and surrounding skin condition.

Psychosocial assessment

Crohn’s disease significantly impairs quality of life. Screen for depression and anxiety, which are prevalent in IBD. Assess the patient’s understanding of their disease, medication adherence barriers, social support, and impact of symptoms on work and relationships. Adolescents require developmental consideration – disease can delay puberty and growth, adding psychosocial complexity.

Medical management

Treatment aims to induce and maintain remission, achieve mucosal healing, and prevent complications. The treat-to-target strategy – using objective markers (endoscopic remission, normalized CRP) rather than symptom relief alone as the endpoint – has become the standard of care.

Corticosteroids

Used for induction of remission during flares. Prednisone (systemic) is effective but carries significant side effects with prolonged use (adrenal suppression, osteoporosis, hyperglycemia, infection risk). Budesonide is an oral corticosteroid formulated for controlled release in the terminal ileum and ascending colon; its high first-pass hepatic metabolism limits systemic side effects, making it preferred for mild-to-moderate ileocecal Crohn’s. Corticosteroids are bridge therapy only – they are not appropriate for long-term maintenance.

Immunomodulators

• Azathioprine (AZA) and 6-mercaptopurine (6-MP): Thiopurines used for maintenance of remission. Slow onset of action (3-6 months). Require monitoring of CBC for myelosuppression and liver function tests. Check thiopurine methyltransferase (TPMT) status before starting – patients with low TPMT are at high risk for severe myelosuppression. NUDT15 genotyping should be checked alongside TPMT: TPMT deficiency explains most thiopurine-related myelosuppression in patients of European and African ancestry, while NUDT15 variants account for most of it in East Asian, South Asian, and Native American populations, where TPMT testing alone would miss the risk.
• Methotrexate: Alternative immunomodulator; requires folic acid supplementation and is contraindicated in pregnancy. (The old FDA pregnancy letter categories were phased out beginning in 2015 under the Pregnancy and Lactation Labeling Rule; methotrexate labeling now carries a narrative contraindication rather than a “category X” designation, and effective contraception is required in patients of childbearing potential.)

Biologics

Biologic therapy targets specific inflammatory mediators and is the cornerstone of moderate-to-severe Crohn’s disease management.

• Anti-TNF agents (infliximab, adalimumab, certolizumab pegol): First-line biologics for moderate-to-severe disease. Infliximab is IV infusion; adalimumab and certolizumab are subcutaneous injections. Screen for latent tuberculosis (TB) with a tuberculin skin test or QuantiFERON-Gold assay before initiating – anti-TNF therapy can reactivate latent TB. Also screen for hepatitis B (reactivation risk).
• Vedolizumab: Gut-selective anti-integrin that blocks lymphocyte trafficking to the GI mucosa. Preferred in patients at higher infection risk (lower systemic immunosuppression).
• Ustekinumab: Anti-IL-12/23 agent; effective for moderate-to-severe Crohn’s, particularly in patients who have lost response to anti-TNF therapy.

Newer agents (IL-23p19 inhibitors and JAK inhibitors)

The Crohn’s treatment landscape changed substantially between 2022 and 2025, and the “anti-TNF first, everything else second” sequence taught in older texts no longer reflects practice. The 2025 AGA guideline on pharmacologic management of moderate-to-severe Crohn’s disease places a group of newer agents alongside infliximab, adalimumab, and ustekinumab as first-line options:

• Risankizumab (Skyrizi): Selective IL-23p19 inhibitor, FDA-approved for moderate-to-severe Crohn’s in December 2022. IV induction followed by subcutaneous maintenance.
• Guselkumab (Tremfya): IL-23p19 inhibitor approved for Crohn’s in 2025, with subcutaneous induction and maintenance formulations approved in September 2025.
• Mirikizumab (Omvoh): IL-23p19 inhibitor, FDA-approved for Crohn’s in January 2025 on the strength of the VIVID-1 trial.
• Upadacitinib (Rinvoq): Oral JAK inhibitor. Its FDA label was updated in October 2025 to allow use before an anti-TNF agent has been tried. As an oral small molecule rather than an injected antibody, it carries a different monitoring profile – a boxed warning covering serious infection, malignancy, major adverse cardiovascular events, thrombosis, and mortality. Nurses should reinforce lipid and CBC monitoring and the importance of reporting any infection symptom promptly.

For a comprehensive review of biologic drug classifications and mechanism of action, see the drug classifications nursing guide.

Nursing interventions

Nutritional support

Malnutrition is a primary nursing concern in Crohn’s disease. Collaborate with a registered dietitian to develop a nutrition plan. During acute flares, enteral nutrition (EN) via nasogastric tube may be required; EN can also serve as primary therapy in pediatric Crohn’s to induce remission while supporting growth. Exclusive enteral nutrition is preferred over parenteral nutrition whenever the gut is functional, as EN preserves gut integrity. Provide small, frequent meals. Identify and help patients avoid personal trigger foods while maintaining nutritional adequacy.

Pain management

Abdominal cramping is managed with antispasmodics for functional symptoms. Avoid NSAIDs – they worsen intestinal inflammation and can precipitate flares. Opioids are a last resort due to risk of dependency and the risk of masking obstruction or perforation. Assess pain systematically using a validated pain scale and document response to interventions.

Perianal skin care

Frequent diarrhea and perianal fistulas compromise skin integrity. Use barrier creams (zinc oxide, petrolatum) to protect perianal skin after each bowel movement. Assess fistula output – document volume, character, and odor. Provide wound care per surgeon orders for perianal abscesses post-drainage. Sitz baths improve comfort and promote hygiene.

Fluid and electrolyte replacement

Administer IV fluids and electrolyte replacement as ordered during acute flares. Monitor intake and output. Correct hypokalemia, hypomagnesemia, and metabolic acidosis from diarrheal losses. Assess for refeeding syndrome in severely malnourished patients receiving nutrition support.

Medication monitoring

• Corticosteroids: Monitor blood glucose (steroid-induced hyperglycemia), blood pressure, mood changes, and signs of infection. Taper slowly – never stop abruptly.
• Thiopurines: Check CBC weekly for the first month, then every 3 months. Watch for leukopenia, thrombocytopenia, and hepatotoxicity.
• Biologics: Before infusion, screen for signs of infection (fever, cough, dysuria). Assess infusion site reactions during IV administration. Educate patients that biologics increase infection susceptibility, including opportunistic infections.

Patient education

• Medication adherence is critical – missing doses leads to loss of remission and development of antibodies to biologic agents
• Smoking cessation is mandatory – smoking accelerates Crohn’s disease progression and increases the risk of surgery
• Recognize signs of a flare: increased stool frequency, recurrent abdominal pain, new perianal symptoms, fever
• Contact provider before stopping any immunosuppressive medication
• Routine vaccinations: avoid live vaccines while on immunosuppressive therapy; ensure pneumococcal and influenza vaccines are current before starting biologics

Surgical considerations

Older figures put lifetime surgical risk at 70-80%, but that number comes from pre-biologic cohorts and overstates current risk. Population-based studies spanning the biologic era show a clear decline: in a Scottish cohort the 5-year cumulative risk of surgery fell from 20.4% in patients diagnosed 2000-2004 to 13.0% in those diagnosed 2014-2017, and Hungarian data show the 10-year probability of first resection dropping from 46.1% in the pre-biologic era to roughly a third thereafter. Surgery remains common, and it is still not curative. The most common indications are bowel obstruction from strictures, intra-abdominal abscess, fistulas refractory to medical therapy, and failure of medical management.

Bowel resection removes the most severely affected segment, typically including an ileocecal resection for terminal ileal disease. Postoperative recurrence at the anastomotic site occurs in up to 80% of patients within 10 years, making ongoing medical maintenance therapy essential after surgery.

Short bowel syndrome is a risk when extensive resection reduces the functional intestinal absorptive surface area. Patients with less than 150-200 cm of functional small intestine may require long-term parenteral nutrition.

Ileostomy or colostomy may be created for fecal diversion in complex perianal disease or after resection of severely diseased colonic segments. Nursing care includes stoma site assessment, pouching system management, and patient education on self-care and output monitoring.

Complications

Crohn’s disease carries a significant complication burden, many of which require urgent nursing recognition:

• Fistulas: Abnormal tracts connecting segments of bowel to each other (enteroenteric), bladder (enterovesical – presents with pneumaturia or fecaluria), vagina (enterovaginal), or skin (enterocutaneous). Require medical management with biologics and/or surgical repair.
• Abscesses: Intra-abdominal or perianal abscesses from transmural inflammation require drainage. A fever with RLQ pain and tender mass in a Crohn’s patient should prompt imaging to rule out abscess.
• Strictures: Fibrotic narrowing of the bowel lumen causes partial or complete obstruction. Patients present with cramping pain, distension, nausea, and vomiting. High-output ileostomy or obstructive symptoms warrant urgent evaluation.
• Malnutrition: A direct consequence of malabsorption, increased metabolic demand, and restricted intake. Increases operative mortality and wound healing complications.
• Vitamin B12 deficiency: Terminal ileum disease or resection eliminates the only site of B12 absorption. Monitor B12 levels; administer parenteral replacement as needed.
• Oxalate kidney stones: Fat malabsorption leaves excess free fatty acids in the colon that bind calcium, preventing calcium oxalate formation. Unbound oxalate is then hyperabsorbed – precipitating calcium oxalate nephrolithiasis. Encourage hydration and a low-oxalate diet.
• Colorectal cancer: Long-standing colonic Crohn’s disease increases colorectal cancer risk, though the risk is lower than in ulcerative colitis. Surveillance colonoscopy is recommended after 8-10 years of disease.
• Growth retardation in children: Chronic inflammation and malnutrition impair linear growth and delay puberty. Pediatric Crohn’s requires close monitoring of height, weight, and bone age.

NCLEX decision scenarios

These scenarios reflect the most commonly tested Crohn’s disease concepts. Work through each before reading the answer.

Scenario 1

A 24-year-old is admitted with a 2-week history of right lower quadrant pain, 6-8 loose non-bloody stools per day, and a 12-pound weight loss. Colonoscopy reveals skip lesions and cobblestone mucosa. Which finding most distinguishes this presentation from ulcerative colitis?

A. Diarrhea and abdominal pain B. Skip lesions on colonoscopy C. Weight loss D. Elevated CRP

Correct answer: B. Skip lesions (areas of inflamed bowel interspersed with normal bowel) are characteristic of Crohn’s disease. Ulcerative colitis produces contiguous inflammation beginning at the rectum. Diarrhea, abdominal pain, weight loss, and elevated CRP occur in both diseases.

Scenario 2

A patient with Crohn’s disease is starting infliximab therapy. Which action is the nurse’s priority before the first infusion?

A. Administer acetaminophen to prevent infusion reactions B. Verify that tuberculosis screening has been completed and reviewed C. Confirm the patient has been NPO for 8 hours D. Obtain a colonoscopy report from the last 12 months

Correct answer: B. Anti-TNF agents (including infliximab) can reactivate latent tuberculosis. TB screening with a tuberculin skin test or QuantiFERON-Gold assay must be completed and reviewed before initiating therapy. Positive latent TB requires treatment before starting biologics.

Scenario 3

A patient who had a surgical resection of the terminal ileum 6 months ago reports new-onset fatigue, tingling in both hands, and difficulty with balance. Laboratory results show a macrocytic anemia. The nurse recognizes these findings as consistent with which complication?

A. Iron deficiency anemia from chronic GI blood loss B. Folate deficiency from jejunal malabsorption C. Vitamin B12 deficiency from loss of terminal ileum D. Copper deficiency from prolonged parenteral nutrition

Correct answer: C. The terminal ileum is the only site of vitamin B12 absorption. After ileal resection, B12 deficiency develops and presents with macrocytic anemia, peripheral neuropathy (tingling in extremities), and subacute combined degeneration (balance and coordination problems). Monthly IM B12 injections are required.

Scenario 4

A nurse is caring for a patient admitted with a Crohn’s disease flare. The patient reports severe right lower quadrant pain, fever of 38.9°C, and the nurse palpates a tender mass in the RLQ. What is the priority nursing action?

A. Administer the scheduled dose of prednisone B. Prepare the patient for a colonoscopy C. Notify the provider and anticipate imaging orders D. Encourage oral fluids and a low-residue diet

Correct answer: C. Fever, localized RLQ pain, and a palpable tender mass in a patient with Crohn’s disease are clinical features of an intra-abdominal abscess – a surgical emergency. The nurse must notify the provider immediately; CT imaging will likely be ordered to confirm the diagnosis. Scheduling a colonoscopy is inappropriate in the setting of possible abscess or perforation.

Scenario 5

A patient with Crohn’s disease involving the colon is being discharged on azathioprine. Which teaching point is most important?

A. Take the medication with antacids to minimize GI side effects B. Expect significant improvement in symptoms within 2 weeks C. Report any signs of infection, unusual bruising, or bleeding promptly D. Avoid all dairy products while taking this medication

Correct answer: C. Azathioprine is an immunomodulator that suppresses bone marrow activity, causing myelosuppression. Patients must report signs of infection (fever, chills), leukopenia-related symptoms, or thrombocytopenia (unusual bruising, bleeding). CBC monitoring is required regularly during therapy. Azathioprine has a slow onset (3-6 months) – not 2 weeks.

Scenario 6

A patient with Crohn’s disease and significant ileal involvement is found to have new-onset calcium oxalate kidney stones. The nurse understands that the most likely mechanism is:

A. Decreased fluid intake from fear of diarrhea B. Hyperabsorption of oxalate from the colon due to fat malabsorption C. Increased urinary calcium from corticosteroid-induced bone resorption D. Alkaline urine from bicarbonate supplementation

Correct answer: B. In ileal Crohn’s disease, fat malabsorption allows excess free fatty acids to bind intraluminal calcium, preventing calcium oxalate complex formation. Unbound oxalate is then hyperabsorbed by the colon, leading to hyperoxaluria and calcium oxalate nephrolith formation. This mechanism is specific to diseases involving the ileum or ileal resection.

Scenario 7

Which statement by a patient with newly diagnosed Crohn’s disease indicates a need for further teaching?

A. “I should call my doctor if I develop a fever or new perianal pain.” B. “Quitting smoking may help reduce my disease activity.” C. “I can stop my biologic injection if I feel well for 6 months.” D. “I need to let my dentist know about my medications before any procedures.”

Correct answer: C. Patients should never discontinue biologic therapy without consulting their gastroenterologist. Stopping biologics during remission can lead to loss of response, development of anti-drug antibodies, and disease flare. Feeling well is a goal of therapy – it does not mean the medication is no longer needed. All other statements are correct.

Key takeaways

• Crohn’s disease is a transmural, relapsing-remitting inflammatory bowel disease that can affect any part of the GI tract, most commonly the terminal ileum
• Transmural inflammation explains Crohn’s hallmark complications: fistulas, abscesses, strictures, and perianal disease
• Terminal ileum involvement uniquely causes B12 deficiency, bile salt malabsorption, and fat-soluble vitamin deficiency
• Unlike ulcerative colitis, Crohn’s disease is not surgically curable – disease recurs at anastomotic sites
• Screen for latent TB before initiating anti-TNF biologic therapy; never skip this step
• Nursing priorities during a flare: nutritional support, fluid/electrolyte replacement, perianal skin care, pain management, and close monitoring for infectious complications (abscess, perforation)
• Smoking worsens Crohn’s disease – cessation counseling is a nursing intervention, not optional education

References

[1] Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: management of Crohn’s disease in adults. American Journal of Gastroenterology. 2025;120(6):1225–1264. doi:10.14309/ajg.0000000000003465 (Supersedes the 2018 edition, Lichtenstein et al., Am J Gastroenterol 2018;113(4):481–517, doi:10.1038/ajg.2018.27.)

[2] Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. Journal of Crohn’s and Colitis. 2020;14(1):4–22. doi:10.1093/ecco-jcc/jjz180

[3] Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease (SONIC trial). New England Journal of Medicine. 2010;362(15):1383–1395. doi:10.1056/NEJMoa0904492

[4] D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–667. doi:10.1016/S0140-6736(08)60304-9

[5] Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD). Gastroenterology. 2021;160(5):1570–1583. doi:10.1053/j.gastro.2020.12.031

[6] Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–2789. doi:10.1016/S0140-6736(17)32641-7

[7] Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease (PRECISE 2 trial). New England Journal of Medicine. 2007;357(3):239–250. doi:10.1056/NEJMoa062897

[8] Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. New England Journal of Medicine. 2013;369(8):711–721. doi:10.1056/NEJMoa1215739

[9] Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. New England Journal of Medicine. 2012;367(16):1519–1528. doi:10.1056/NEJMoa1203572

[10] Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. doi:10.1016/S0140-6736(02)08512-4

[11] Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. New England Journal of Medicine. 2004;350(9):876–885. doi:10.1056/NEJMoa030815

[12] Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and medical management. Journal of Crohn’s and Colitis. 2017;11(1):3–25. doi:10.1093/ecco-jcc/jjw168

[13] Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease. Journal of Crohn’s and Colitis. 2011;5(5):477–483. doi:10.1016/j.crohns.2011.06.009

[14] Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Current management. Journal of Crohn’s and Colitis. 2010;4(1):28–62. doi:10.1016/j.crohns.2009.12.002

[15] Benchimol EI, Fortinsky KJ, Gozdyra P, van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflammatory Bowel Diseases. 2011;17(1):423–439. doi:10.1002/ibd.21349

[16] Scott FI, Ananthakrishnan AN, Click B, et al. AGA living clinical practice guideline on the pharmacologic management of moderate-to-severe Crohn’s disease. Gastroenterology. 2025;169(7):1397–1448. doi:10.1053/j.gastro.2025.09.038

[17] D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–2030. doi:10.1016/S0140-6736(22)00467-6

[18] Ferrante M, D’Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled study (VIVID-1). Lancet. 2024;404(10470):2423–2436. doi:10.1016/S0140-6736(24)01762-8